Pharmacokinetics and Pharmacodynamics Practice Questions

Q: Which of the following drugs is deposited in the muscles?

Digoxin. **Explanation:** The correct answer is **Digoxin**. This question tests the concept of **Volume of Distribution ($V_d$)** and tissue-specific binding [1]. **1. Why Digoxin is Correct:** Digoxin has an exceptionally large volume of distribution (~5–7 L/kg) because it is extensively sequestered in peripheral tissues, specifically **skeletal muscle** and the heart [1]. It binds to the Na+/K+-ATPase pump in these tissues [1],[3]. Because skeletal muscle represents a large percentage of total body mass, it serves as the primary reservoir for Digoxin [1]. * **Clinical Correlation:** In obese patients, Digoxin dosage should be calculated based on **Lean Body Weight (LBW)** rather than total body weight, as Digoxin does not distribute into adipose tissue. **2. Why the Other Options are Incorrect:** * **Verapamil:** While it has a large $V_d$, it does not show the characteristic high-affinity sequestration in skeletal muscle that Digoxin does. It is primarily metabolized by the liver. * **Adenosine:** It has an extremely short half-life (<10 seconds) because it is rapidly taken up by erythrocytes and endothelial cells and metabolized. It does not have time to deposit in muscles. * **Phenytoin:** It is highly protein-bound (mainly to albumin) and follows zero-order kinetics at high therapeutic concentrations [2]. It does not sequester in skeletal muscle. **High-Yield NEET-PG Pearls:** * **Tissue Reservoirs:** * **Muscle:** Digoxin [1] * **Adipose Tissue:** Thiopental, Amiodarone * **Bone/Teeth:** Tetracyclines, Fluoride * **Retina:** Chloroquine (binds to melanin) * **Liver:** Chloroquine, Emetine * **Digoxin Monitoring:** Since Digoxin is sequestered in muscles, plasma levels do not reflect tissue levels immediately after administration. Blood for Therapeutic Drug Monitoring (TDM) should be drawn at least **6–8 hours** after the last dose to allow for distribution [4].

Q: An agonist has which of the following characteristics?

Affinity with intrinsic activity of 0. **Explanation** In pharmacology and neuroanatomy, the interaction between a ligand and a receptor is defined by two key properties: **Affinity** (the ability of a drug to bind to a receptor) and **Intrinsic Activity/Efficacy** (the ability of a drug to activate the receptor and produce a biological response). **Why Option A is Correct:** An **Antagonist** (often referred to as a "blocker") possesses **affinity** for the receptor, allowing it to occupy the binding site. However, it has an **intrinsic activity of 0**. This means it does not trigger any conformational change to activate the receptor; instead, it simply prevents an agonist from binding, thereby inhibiting its effect. **Analysis of Incorrect Options:** * **Option B (Intrinsic Activity of 1):** This describes a **Full Agonist**. These drugs bind to the receptor and produce the maximum possible biological response. * **Option C (Intrinsic Activity of -1):** This describes an **Inverse Agonist**. These drugs bind to the same receptor as an agonist but produce a response that is pharmacologically opposite to that of the agonist (only possible in receptors with constitutive activity). * **Partial Agonists** (not listed) have an intrinsic activity between 0 and 1. **NEET-PG High-Yield Pearls:** 1. **Competitive Antagonism:** Shifts the Dose-Response Curve (DRC) to the **right**, increasing the $ED_{50}$ but maintaining the same $V_{max}$ (can be overcome by increasing agonist concentration). 2. **Non-competitive Antagonism:** Flattens the DRC, decreasing the $V_{max}$ (cannot be overcome by more agonist). 3. **Key Example:** Naloxone is a competitive antagonist at opioid receptors, used to reverse respiratory depression in overdose cases.

Q: A 70 kg man was given a drug at a dose of 100 mg/kg body weight. The drug's half-life (t1/2) is 10 hours and the initial plasma concentration is 1.9 mg/ml. Which of the following statements is true?

The elimination rate constant (k) is 0.0693 hr^-1.. ### Explanation This question tests your understanding of basic pharmacokinetics, specifically the relationship between half-life ($t_{1/2}$) and the elimination rate constant ($k$). **1. Why Option C is Correct:** The elimination rate constant ($k$) represents the fraction of a drug removed per unit of time. It is inversely proportional to the half-life. The standard formula for a first-order kinetic process is: $k = rac{0.693}{t_{1/2}}$ Given $t_{1/2} = 10$ hours: $k = rac{0.693}{10} = 0.0693 \text{ hr}^{-1}$ This indicates that approximately 6.93% of the drug is eliminated every hour. **2. Why Other Options are Incorrect:** * **Option D:** This is a decimal point error ($6.93$ vs $0.0693$). * **Options A & B (Clearance):** To calculate Clearance ($CL$), we first need the Volume of Distribution ($V_d$). * $V_d = \frac{\text{Total Dose}}{\text{Initial Plasma Concentration}}$ * Total Dose = $100 \text{ mg/kg} \times 70 \text{ kg} = 7000 \text{ mg}$. * $V_d = \frac{7000 \text{ mg}}{1.9 \text{ mg/ml}} \approx 3684 \text{ ml}$ or $3.68 \text{ L}$. * $CL = k \times V_d = 0.0693 \times 3.68 \approx 0.255 \text{ L/hr}$ [1]. Neither 0.02 nor 20 L/hr matches the calculated clearance. **3. NEET-PG High-Yield Pearls:** * **First-Order Kinetics:** A constant **fraction** of drug is eliminated per unit time (most drugs). $t_{1/2}$ is constant. * **Zero-Order Kinetics:** A constant **amount** of drug is eliminated per unit time (e.g., Ethanol, Phenytoin, Aspirin at high doses). $t_{1/2}$ is variable. * **Steady State:** It takes approximately **4 to 5 half-lives** to reach steady-state concentration ($C_{ss}$) and the same amount of time to completely eliminate a drug from the body. * **Loading Dose:** Depends primarily on $V_d$ ($LD = V_d \times C_p$) [1]. * **Maintenance Dose:** Depends primarily on $CL$ ($MD = CL \times C_{ss}$).

Q: Urinary alkalinizing agents are administered in case of poisoning due to which type of drugs?

Weak acids. **Explanation:** The principle behind urinary alkalinization is the **Ion Trapping Phenomenon**, which is governed by the Henderson-Hasselbalch equation. **1. Why Weak Acids are the Correct Answer:** Weakly acidic drugs (e.g., Salicylates, Phenobarbitone) exist in an equilibrium between ionized (charged) and unionized (uncharged) forms. In an alkaline medium (high pH), weak acids become **ionized**. Since ionized molecules are lipid-insoluble, they cannot diffuse back across the renal tubular epithelium into the bloodstream. This "traps" the drug in the tubular lumen, significantly increasing its renal clearance and excretion. **2. Why the Other Options are Incorrect:** * **Weak Bases:** In an alkaline urine, weak bases remain unionized (lipid-soluble), allowing them to be easily reabsorbed into the systemic circulation. To enhance the excretion of weak bases (e.g., Amphetamines), **urinary acidification** (using Ammonium Chloride) is required. * **Strong Acids/Bases:** These are already highly ionized at physiological pH levels. Their excretion is generally not significantly altered by minor shifts in urinary pH achieved through clinical alkalinization. **Clinical Pearls for NEET-PG:** * **Agent of Choice:** **Sodium Bicarbonate ($NaHCO_3$)** is the standard agent used to alkalinize urine (Target pH: 7.5–8.5). * **Classic Examples:** Forced alkaline diuresis is most commonly tested for **Salicylate (Aspirin)** and **Barbiturate** poisoning. * **Contraindication:** Do not alkalinize urine in patients with renal failure or congestive heart failure due to the risk of fluid and sodium overload. * **Mnemonic:** **"Like dissolves in Like"** (Unionized/Absorbed); **"Opposites Ionize"** (Ionized/Excreted). Acidic drug + Basic urine = Excretion.

Q: Which of the following characteristics is associated with a high volume of distribution for a drug?

Lipophilicity. The **Volume of Distribution ($V_d$)** is a theoretical volume that relates the amount of drug in the body to its plasma concentration ($V_d = \text{Total amount of drug} / \text{Plasma concentration}$). 1. Why Lipophilicity is Correct: Lipophilic (fat-soluble) drugs easily cross biological membranes and leave the vascular compartment to enter peripheral tissues and adipose stores [2]. Because the drug sequestered in tissues is not present in the plasma, the plasma concentration becomes very low. Mathematically, a low denominator (plasma concentration) results in a **high $V_d$** [1]. 2. Analysis of Incorrect Options: Hydrophilicity: Water-soluble drugs are polar and cannot easily cross lipid bilayers. They tend to remain confined to the plasma or extracellular fluid, resulting in a **low $V_d$**. High Protein Binding: Drugs that bind strongly to plasma proteins (like albumin) are "trapped" within the vascular compartment. This maintains a high plasma concentration, leading to a **low $V_d$**. (Conversely, high *tissue* binding increases $V_d$) [1]. Low Therapeutic Index: This refers to the safety profile of a drug (the ratio between toxic and effective doses) and has no direct physiological correlation with the volume of distribution. High-Yield Clinical Pearls for NEET-PG: Drug Example: **Chloroquine** has a massive $V_d$ (~15,000 L) because it binds extensively to tissues (retina/liver) [1]. Hemodialysis: Drugs with a high $V_d$ cannot be efficiently removed by hemodialysis because most of the drug is outside the bloodstream. Loading Dose: $V_d$ is the primary determinant used to calculate the Loading Dose ($LD = V_d \times \text{Target Plasma Concentration}$) [3]. Aging/Obesity: In elderly or obese patients, the $V_d$ for lipophilic drugs (e.g., Diazepam) increases due to a higher body fat percentage.

Q: Which is the most common cytochrome P450 enzyme associated with drug metabolism?

CYP3A4/5. **Explanation:** **1. Why CYP3A4/5 is the Correct Answer:** CYP3A4 is the most abundant and clinically significant cytochrome P450 isoform in humans. It accounts for approximately **30% of the total CYP content in the liver** and is responsible for the metabolism of nearly **50% of all clinically used drugs**. Its high expression in both the liver and the intestinal wall makes it a major determinant of first-pass metabolism and oral bioavailability. **2. Analysis of Incorrect Options:** * **CYP2D6 (Option B):** While it is the second most important enzyme and metabolizes about 25% of drugs (including beta-blockers, antidepressants, and opioids like codeine), it is highly **polymorphic**. It is not the most common by volume or total drug substrate count. * **CYP2C8/9 (Option C):** These metabolize roughly 15% of drugs. CYP2C9 is notable for metabolizing drugs with narrow therapeutic indices, such as **Warfarin** and **Phenytoin**. * **CYP2C19 (Option D):** This enzyme metabolizes about 5% of drugs, including **Clopidogrel** (a prodrug) and Proton Pump Inhibitors (PPIs). **3. High-Yield Clinical Pearls for NEET-PG:** * **Inducers of CYP3A4:** Rifampicin, Phenytoin, Carbamazepine, St. John’s Wort (Mnemonic: **GPRS Cell Phone** - Griseofulvin, Phenytoin, Rifampicin, Smoking, Carbamazepine, Phenobarbitone). * **Inhibitors of CYP3A4:** Ketoconazole, Erythromycin, **Grapefruit juice**, Ritonavir (Mnemonic: **VITAMIN K** - Valproate, Isoniazid, Troleandomycin, Amiodarone, Macrolides, Itraconazole, NNRTIs, Ketoconazole). * **Suicide Inhibitor:** Grapefruit juice irreversibly inhibits CYP3A4 in the intestinal wall. * **Genetic Polymorphism:** Most commonly associated with **CYP2D6** (Poor vs. Ultra-rapid metabolizers) and **CYP2C19**.

Question 1

Which of the following drugs is deposited in the muscles?

Accepted Answer

Digoxin

Answer

Verapamil

Answer

Adenosine

Answer

Phenytoin

Question 2

An agonist has which of the following characteristics?

Accepted Answer

Affinity with intrinsic activity of 0

Answer

Affinity with intrinsic activity of 1

Answer

Affinity with intrinsic activity of -1

Answer

None of the above

Question 3

Which drug transport process requires energy?

Accepted Answer

Active transport

Answer

Passive diffusion

Answer

Convective current

Answer

Pinocytosis

Question 4

A 70 kg man was given a drug at a dose of 100 mg/kg body weight. The drug's half-life (t1/2) is 10 hours and the initial plasma concentration is 1.9 mg/ml. Which of the following statements is true?

Accepted Answer

The elimination rate constant (k) is 0.0693 hr^-1.

Answer

The clearance (CL) is 0.02 litre/hr.

Answer

The clearance (CL) is 20 litre/hr.

Answer

The elimination rate constant (k) is 6.93 hr^-1.

Question 5

Urinary alkalinizing agents are administered in case of poisoning due to which type of drugs?

Accepted Answer

Weak acids

Answer

Weak bases

Answer

Strong bases

Answer

Strong acids

Question 6

Which of the following drug combinations represents psychological antagonism?

Accepted Answer

Prostacycline-thromboxane

Answer

Heparin-protamine

Answer

Adrenaline-phenoxybenzamine

Answer

Physostigmine-acetylcholine

Question 7

Which of the following characteristics is associated with a high volume of distribution for a drug?

Accepted Answer

Lipophilicity

Answer

Hydrophilicity

Answer

High protein binding

Answer

Low therapeutic index

Question 8

An elderly patient presents with myocardial infarction and a severe ventricular arrhythmia. The chosen antiarrhythmic drug has a narrow therapeutic window, with a minimum toxic plasma concentration 1.5 times the minimum therapeutic plasma concentration. The drug's half-life is 6 hours. It is crucial to maintain the plasma concentration above the minimum therapeutic level to prevent lethal arrhythmia. Which of the following dosing regimens is most appropriate?

Accepted Answer

Constant intravenous infusion

Answer

Once daily

Answer

Twice daily

Answer

Four times daily

Question 9

Which of the following is an ionic channel?

Accepted Answer

Nicotinic cholinergic receptors

Answer

$\alpha$1 receptors

Answer

$\beta$1 receptors

Answer

Muscarinic cholinergic receptors

Question 10

Which is the most common cytochrome P450 enzyme associated with drug metabolism?

Accepted Answer

CYP3A4/5

Answer

CYP2D6

Answer

CYP2C8/9

Answer

CYP2C19

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?